On the contrary, poziotinib (a tyrosine kinase inhibitor employed in HER2 exon 20 mutant Non-Small Cell Lung Cancer, NSCLC), mainly metabolized by CYP3A4, was found to significantly inhibit the metabolism of vonoprazan [48]. Here, ERBB2 is linked to non-small cell lung carcinoma.